Antibacterianos: Principais classes, mecanismos de ação e resistência
Palabras clave:
Antibacterianos; Resistência; GenesResumen
entender o mecanismo de ação dos fármacos antimicrobianos e compreender os mecanismos
pelos quais as bactérias conseguem resistir ao ataque destes fármacos é essencial para o desenvolvimento
de meios para potencializar a eficácia e mimetizar o desenvolvimento da resistência bacteriana. O objetivo
deste trabalho foi realizar revisão sobre os principais mecanismos de ação dos agentes antibacterianos e
mecanismos de resistência das bactérias a essas drogas. Para tal, fontes primárias e secundárias de dados
nacionais e internacionais foram consultadas. Os mecanismos de ação das principais drogas antibacterianas
foram explorados e exemplificados, bem como mecanismos de resistência bacteriana. A antibioticoterapia
como tratamento de infecções bacterianas está cada vez mais ineficiente em decorrência da emergência
de bactérias resistentes a múltiplos fármacos. Há, portanto, a necessidade global de descobertas de novas
drogas para o tratamento de infecções bacterianas.
Descargas
Los datos de descargas todavía no están disponibles.
Citas
1. TENOVER, F. C. Mechanisms of
Antimicrobial Resistance in Bacteria. The American
Journal of Medicine. v. 119, n. 6A, p. S3-S10, jun.
2006.
2. HOWARD, S. J. et al. Antibiotic resistance:
global response needed. The Lancet Infectious
Diseases. v. 13, n. 12, p. 1001-3, dez. 2013.
3. LUPO, A.; COYNE, S.; BERENDONK, T.
U. Origin and evolution of antibiotic resistance: the
common mechanisms of emergence and spread in
water bodies. Frontiers in Microbiology. v. 3, n. 18,
jan. 2012. Disponível em: < https://www.ncbi.nlm.
nih.gov/pmc/articles/PMC3266646/>. Acesso em:
26 Out. 2016.
4. DAVIES, J.; DAVIES, D. Origins and
evolution of antibiotic resistance. Microbiology
and Molecular Biology Reviews. v. 74, n. 3, p. 417-
33, set. 2010.
5. WEI, W. J. et al. New delhi metallo-βlactamase-mediated carbapenem resistance: origin,
diagnosis, treatment and public health concern.
Chinese Medical Journal. v. 128, n. 14, p. 1969-76,
jul. 2015.
6. CARVALHO, A. A. et al. Characterization
and molecular epidemiology of extensively
prevalent, nosocomial, isolates of the drug-resistant
Acinetobacter spp. Genetics and Molecular
Research. v. 15, n. 3, ago. 2016. Disponível em: <
http://www.funpecrp.com.br/gmr/year2016/vol15-
3/pdf/gmr8608.pdf>. Acesso em: 26 Out.
7. LAXMINARAYAN, R. et al. Antibiotic
resistance - the need for global solutions. The
Lancet Infectious Diseases. v. 13, n. 12, p. 1057-
98, dez. 2013.
8. FRIEDMAN, N. D.; TEMKIN, E.;
CARMELI, Y. The negative impact of antibiotic
resistance. Clinical Microbiology and Infection. v.
22, n. 5, p. 416-22, mai. 2016.
9. BRUNTON, L. L.; CHABNER, B.
A.; KNOLLMANN, B. C. (Orgs.). Goodman
and Gilman's the Pharmacological Basis of
Therapeutics. 12. ed. New York: McGraw-Hill,
2011.
10. RANG, H. P. et al. Rang & Dale’s
Pharmacology. 8. ed. London: Elsevier Churchill
Livingstone, 2015.
11. CONSTANT, J. M. C.; CONSTANT, A. B.
L. Antibióticos e Quimioterápicos Antimicrobianos.
2. ed. São Paulo: Savier, 2015.
12. TORTORA, G. J.; FUNKE, B. R.; CASE,
C. L. Microbiology: An Introduction. 12. ed. New
York: Pearson Benjamin Cummings, 2015.
13. BERTONCHELI, C. M.; HÖRNER, R.
Uma revisão sobre metalo-β-lactamases. Revista
Brasileira de Ciências Farmacêuticas. v. 44, n. 4,
p. 577-99, out-dez. 2008.
14. AVENT, M. L. et al. Current use of
aminoglycosides: indications, pharmacokinetics
and monitoring for toxicity. Internal Medicine
Journal. v. 41, n. 6, p. 441-9, jun. 2011.
15. KAYE, K. S. et al. Agents of Last Resort:
Polymyxin Resistance. Infectious Disease Clinics
of North America. v. 30, n. 2, p. 391-414, jun. 2016.
16. MENDES, C. A. C.; BURDMANN, E.
A. Polimixinas - Revisão com ênfase na sua
nefrotoxicidade. Revista da Associação Médica
Brasileira. v. 55, n. 6, p. 752-59, 2009.
17. GIRARDELLO, R.; GALES, A. C.
Resistência às polimixinas: velhos antibióticos,
últimas opções terapêuticas. Revista de
Epidemiologia e Controle da Infecção. v. 2, n. 2, p.
66-9, 2012.
18. ALÓS, J. I. Quinolonas. Enfermedades
Infecciosas y Microbiología Clínica. v. 27, n. 5, p.
290-97, mai. 2009.
19. GÖBEL, A. et al. Occurrence and
sorption behavior of sulfonamides, macrolides,
and trimethoprim in activated sludge treatment.
Environmental Science and Technology. v. 39, n.
11, p. 3981-9, jun. 2005.
20. GÖBEL, A. et al. Fate of sulfonamides,
macrolides, and trimethoprim in different
wastewater treatment technologies. The Science of
the Total Environment. v. 372, n. 2, p. 361-71, jan.
2007.
21. BLAIR, J. M. A. et al. Molecular
mechanisms of antibiotic resistance. Nature
Reviews Microbiology. v. 13, n. 1, p. 42-51, jan.
2015.
22. CORNAGLIA, G.; GIAMARELLOU,
H.; ROSSOLINI, G. M. Metallo-β-lactamases: a
last frontier for β-lactams?. The Lancet Infectious
Diseases. v. 11, n. 5, p. 381-93, mai. 2011.
23. QUEENAN, A. M.; BUSH, K.
Carbapenemases: the Versatile β-Lactamases.
Clinical Microbiology Reviews. v. 20, n. 3, p. 440–
58, jul. 2007.
24. DJAHMI, N. et al. Epidemiology of
carbapenemase-producing Enterobacteriaceae
and Acinetobacter baumannii in Mediterranean
Countries. BioMed Research International. v. 2014,
n. 1, mai. 2014.
25. BUSH, K. Proliferation and significance of
clinically relevant β-lactamases. Annals of the New
York Academy of Sciences. v. 1277, n. 2013, p. 84-
90, jan. 2013.
26. D'ANDREA, M. M. et al. CTX-M-type
β-lactamases: a successful story of antibiotic
resistance. International Journal of Medical
Microbiology. v. 303, n. 6-7, p. 305-17, ago. 2013.
27. ALEKSHUN, M. N.; LEVY, S. B. Molecular
mechanisms of antibacterial multidrug resistance.
Cell. v. 128, n. 6, p. 1037-50, mar. 2007.
28. BHARDWAJ, A. K.; MOHANTY, P.
Bacterial efflux pumps involved in multidrug
resistance and their inhibitors: rejuvinating the
antimicrobial chemotherapy. Recent Patents on
Anti-infective Drug Discovery. v. 7, n. 1, p. 73-89,
abr. 2012.
29. LI, X. Z.; PLÉSIAT, P.; NIKAIDO, H. The
challenge of efflux-mediated antibiotic resistance
in Gram-negative bacteria. Clinical Microbiology
Reviews. v. 28, n. 2, p. 337-418, abr. 2015.
30. NIKAIDO, H.; PAGÈS, J. M. Broadspecificity efflux pumps and their role in multidrug
resistance of Gram-negative bacteria. FEMS
Microbiology Reviews. v. 36, n. 2, p. 340-63, mar.
2012.
31. YOON, E. J.; COURVALIN, P.; GRILLOTCOURVALIN, C. RND-type efflux pumps in
multidrug-resistant clinical isolates of Acinetobacter
baumannii: major role for AdeABC overexpression
and AdeRS mutations. Antimicrobial Agents and
Chemotherapy. v. 57, n. 7, p. 2989-95, abr. 2013.
32. COYNE, S.; COURVALIN, P.; PÉRICHON,
B. Efflux-mediated antibiotic resistance in
Acinetobacter spp. Antimicrobial Agents and
Chemotherapy. v. 55, n. 3, p. 947-53, mar. 2011.
33. WRIGHT, G. D. Molecular mechanisms of
antibiotic resistance. Chemical Communications. v.
47, n. 14, p. 4055-61, abr. 2011.
34. WILSON, D. N. Ribosome-targeting
antibiotics and mechanisms of bacterial resistance.
Nature Reviews Microbiology. v. 12, n. 1, p. 35-48,
jan. 2014.
35. CHEAH, S. E. et al. Colistin and polymyxin
B dosage regimens against Acinetobacter
baumannii: Differences in activity and the
emergence of resistance. Antimicrobial Agents and
Chemotherapy. v. 60, n. 7, p. 3921-33, jun. 2016.
36. CHEAH, S. E. et al. Polymyxin Resistance
in Acinetobacter baumannii: Genetic Mutations and
Transcriptomic Changes in Response to Clinically
Relevant Dosage Regimens. Scientific Reports. v.
6, n. 26233, mai. 2016. Disponível em: <http://
www.nature.com/articles/srep26233>. Acesso em:
26 Out. 2016.
37. EPAND, R. M. et al. Molecular mechanisms
of membrane targeting antibiotics. Biochimica Et
Biophysica Acta. v. 1858, n. 5, p. 980-7, mai. 2016.
38. KANETI, G.; MEIR, O.; MOR, A.
Controlling bacterial infections by inhibiting
proton-dependent processes. Biochimica Et
Biophysica Acta. v. 1858, n. 5, p. 995-1003, mai.
2016.
39. HAN, L. et al. Structure of the BAM
complex and its implications for biogenesis of
outer-membrane proteins. Nature Structural and
Molecular Biology. v. 23, n. 3, p. 192-6, mar. 2016.
40. GU, Y. et al. Structural basis of outer
membrane protein insertion by the BAM complex.
Nature. v. 531, n. 7592, p. 64-9, mar. 2016.
41. BAKELAR, J.; BUCHANAN, S. K.;
NOINAJ, N. The structure of the β-barrel assembly
machinery complex. Science. v. 351, n. 6269, p.
180-6, jan. 2016.
42. LEYTON, D. L.; BELOUSOFF, M. J.;
LITHGOW, T. The β-Barrel Assembly Machinery
Complex. Methods in Molecular Biology. v. 501, n.
7467, p. 385-90, set. 2013.
Antimicrobial Resistance in Bacteria. The American
Journal of Medicine. v. 119, n. 6A, p. S3-S10, jun.
2006.
2. HOWARD, S. J. et al. Antibiotic resistance:
global response needed. The Lancet Infectious
Diseases. v. 13, n. 12, p. 1001-3, dez. 2013.
3. LUPO, A.; COYNE, S.; BERENDONK, T.
U. Origin and evolution of antibiotic resistance: the
common mechanisms of emergence and spread in
water bodies. Frontiers in Microbiology. v. 3, n. 18,
jan. 2012. Disponível em: < https://www.ncbi.nlm.
nih.gov/pmc/articles/PMC3266646/>. Acesso em:
26 Out. 2016.
4. DAVIES, J.; DAVIES, D. Origins and
evolution of antibiotic resistance. Microbiology
and Molecular Biology Reviews. v. 74, n. 3, p. 417-
33, set. 2010.
5. WEI, W. J. et al. New delhi metallo-βlactamase-mediated carbapenem resistance: origin,
diagnosis, treatment and public health concern.
Chinese Medical Journal. v. 128, n. 14, p. 1969-76,
jul. 2015.
6. CARVALHO, A. A. et al. Characterization
and molecular epidemiology of extensively
prevalent, nosocomial, isolates of the drug-resistant
Acinetobacter spp. Genetics and Molecular
Research. v. 15, n. 3, ago. 2016. Disponível em: <
http://www.funpecrp.com.br/gmr/year2016/vol15-
3/pdf/gmr8608.pdf>. Acesso em: 26 Out.
7. LAXMINARAYAN, R. et al. Antibiotic
resistance - the need for global solutions. The
Lancet Infectious Diseases. v. 13, n. 12, p. 1057-
98, dez. 2013.
8. FRIEDMAN, N. D.; TEMKIN, E.;
CARMELI, Y. The negative impact of antibiotic
resistance. Clinical Microbiology and Infection. v.
22, n. 5, p. 416-22, mai. 2016.
9. BRUNTON, L. L.; CHABNER, B.
A.; KNOLLMANN, B. C. (Orgs.). Goodman
and Gilman's the Pharmacological Basis of
Therapeutics. 12. ed. New York: McGraw-Hill,
2011.
10. RANG, H. P. et al. Rang & Dale’s
Pharmacology. 8. ed. London: Elsevier Churchill
Livingstone, 2015.
11. CONSTANT, J. M. C.; CONSTANT, A. B.
L. Antibióticos e Quimioterápicos Antimicrobianos.
2. ed. São Paulo: Savier, 2015.
12. TORTORA, G. J.; FUNKE, B. R.; CASE,
C. L. Microbiology: An Introduction. 12. ed. New
York: Pearson Benjamin Cummings, 2015.
13. BERTONCHELI, C. M.; HÖRNER, R.
Uma revisão sobre metalo-β-lactamases. Revista
Brasileira de Ciências Farmacêuticas. v. 44, n. 4,
p. 577-99, out-dez. 2008.
14. AVENT, M. L. et al. Current use of
aminoglycosides: indications, pharmacokinetics
and monitoring for toxicity. Internal Medicine
Journal. v. 41, n. 6, p. 441-9, jun. 2011.
15. KAYE, K. S. et al. Agents of Last Resort:
Polymyxin Resistance. Infectious Disease Clinics
of North America. v. 30, n. 2, p. 391-414, jun. 2016.
16. MENDES, C. A. C.; BURDMANN, E.
A. Polimixinas - Revisão com ênfase na sua
nefrotoxicidade. Revista da Associação Médica
Brasileira. v. 55, n. 6, p. 752-59, 2009.
17. GIRARDELLO, R.; GALES, A. C.
Resistência às polimixinas: velhos antibióticos,
últimas opções terapêuticas. Revista de
Epidemiologia e Controle da Infecção. v. 2, n. 2, p.
66-9, 2012.
18. ALÓS, J. I. Quinolonas. Enfermedades
Infecciosas y Microbiología Clínica. v. 27, n. 5, p.
290-97, mai. 2009.
19. GÖBEL, A. et al. Occurrence and
sorption behavior of sulfonamides, macrolides,
and trimethoprim in activated sludge treatment.
Environmental Science and Technology. v. 39, n.
11, p. 3981-9, jun. 2005.
20. GÖBEL, A. et al. Fate of sulfonamides,
macrolides, and trimethoprim in different
wastewater treatment technologies. The Science of
the Total Environment. v. 372, n. 2, p. 361-71, jan.
2007.
21. BLAIR, J. M. A. et al. Molecular
mechanisms of antibiotic resistance. Nature
Reviews Microbiology. v. 13, n. 1, p. 42-51, jan.
2015.
22. CORNAGLIA, G.; GIAMARELLOU,
H.; ROSSOLINI, G. M. Metallo-β-lactamases: a
last frontier for β-lactams?. The Lancet Infectious
Diseases. v. 11, n. 5, p. 381-93, mai. 2011.
23. QUEENAN, A. M.; BUSH, K.
Carbapenemases: the Versatile β-Lactamases.
Clinical Microbiology Reviews. v. 20, n. 3, p. 440–
58, jul. 2007.
24. DJAHMI, N. et al. Epidemiology of
carbapenemase-producing Enterobacteriaceae
and Acinetobacter baumannii in Mediterranean
Countries. BioMed Research International. v. 2014,
n. 1, mai. 2014.
25. BUSH, K. Proliferation and significance of
clinically relevant β-lactamases. Annals of the New
York Academy of Sciences. v. 1277, n. 2013, p. 84-
90, jan. 2013.
26. D'ANDREA, M. M. et al. CTX-M-type
β-lactamases: a successful story of antibiotic
resistance. International Journal of Medical
Microbiology. v. 303, n. 6-7, p. 305-17, ago. 2013.
27. ALEKSHUN, M. N.; LEVY, S. B. Molecular
mechanisms of antibacterial multidrug resistance.
Cell. v. 128, n. 6, p. 1037-50, mar. 2007.
28. BHARDWAJ, A. K.; MOHANTY, P.
Bacterial efflux pumps involved in multidrug
resistance and their inhibitors: rejuvinating the
antimicrobial chemotherapy. Recent Patents on
Anti-infective Drug Discovery. v. 7, n. 1, p. 73-89,
abr. 2012.
29. LI, X. Z.; PLÉSIAT, P.; NIKAIDO, H. The
challenge of efflux-mediated antibiotic resistance
in Gram-negative bacteria. Clinical Microbiology
Reviews. v. 28, n. 2, p. 337-418, abr. 2015.
30. NIKAIDO, H.; PAGÈS, J. M. Broadspecificity efflux pumps and their role in multidrug
resistance of Gram-negative bacteria. FEMS
Microbiology Reviews. v. 36, n. 2, p. 340-63, mar.
2012.
31. YOON, E. J.; COURVALIN, P.; GRILLOTCOURVALIN, C. RND-type efflux pumps in
multidrug-resistant clinical isolates of Acinetobacter
baumannii: major role for AdeABC overexpression
and AdeRS mutations. Antimicrobial Agents and
Chemotherapy. v. 57, n. 7, p. 2989-95, abr. 2013.
32. COYNE, S.; COURVALIN, P.; PÉRICHON,
B. Efflux-mediated antibiotic resistance in
Acinetobacter spp. Antimicrobial Agents and
Chemotherapy. v. 55, n. 3, p. 947-53, mar. 2011.
33. WRIGHT, G. D. Molecular mechanisms of
antibiotic resistance. Chemical Communications. v.
47, n. 14, p. 4055-61, abr. 2011.
34. WILSON, D. N. Ribosome-targeting
antibiotics and mechanisms of bacterial resistance.
Nature Reviews Microbiology. v. 12, n. 1, p. 35-48,
jan. 2014.
35. CHEAH, S. E. et al. Colistin and polymyxin
B dosage regimens against Acinetobacter
baumannii: Differences in activity and the
emergence of resistance. Antimicrobial Agents and
Chemotherapy. v. 60, n. 7, p. 3921-33, jun. 2016.
36. CHEAH, S. E. et al. Polymyxin Resistance
in Acinetobacter baumannii: Genetic Mutations and
Transcriptomic Changes in Response to Clinically
Relevant Dosage Regimens. Scientific Reports. v.
6, n. 26233, mai. 2016. Disponível em: <http://
www.nature.com/articles/srep26233>. Acesso em:
26 Out. 2016.
37. EPAND, R. M. et al. Molecular mechanisms
of membrane targeting antibiotics. Biochimica Et
Biophysica Acta. v. 1858, n. 5, p. 980-7, mai. 2016.
38. KANETI, G.; MEIR, O.; MOR, A.
Controlling bacterial infections by inhibiting
proton-dependent processes. Biochimica Et
Biophysica Acta. v. 1858, n. 5, p. 995-1003, mai.
2016.
39. HAN, L. et al. Structure of the BAM
complex and its implications for biogenesis of
outer-membrane proteins. Nature Structural and
Molecular Biology. v. 23, n. 3, p. 192-6, mar. 2016.
40. GU, Y. et al. Structural basis of outer
membrane protein insertion by the BAM complex.
Nature. v. 531, n. 7592, p. 64-9, mar. 2016.
41. BAKELAR, J.; BUCHANAN, S. K.;
NOINAJ, N. The structure of the β-barrel assembly
machinery complex. Science. v. 351, n. 6269, p.
180-6, jan. 2016.
42. LEYTON, D. L.; BELOUSOFF, M. J.;
LITHGOW, T. The β-Barrel Assembly Machinery
Complex. Methods in Molecular Biology. v. 501, n.
7467, p. 385-90, set. 2013.
Descargas
Publicado
2020-12-06
Cómo citar
SANTOS NOGUEIRA, H. .; ERICSSON DE OLIVEIRA XAVIER, A. R. .; DE SOUSA XAVIER, M. A. .; AMARAL CARVALHO, A. .; ATAÍDE MONÇÃO, G. .; PRATES BARRETO, N. A. . Antibacterianos: Principais classes, mecanismos de ação e resistência . Revista Unimontes Científica, [S. l.], v. 18, n. 2, p. 96–108, 2020. Disponível em: https://www.periodicos.unimontes.br/index.php/unicientifica/article/view/1811. Acesso em: 23 nov. 2024.
Número
Sección
Artigos de Revisão
